US 12,440,488 B2 · Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension

Abstract

A method of treating COPD, Asthma, Pneumonia, Bronchitis, Cystic Fibrosis, Pulmonary Edema, Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis and PAH in a patient. One embodiment includes administering a vasodilator prostacyclin analogue, such as Beraprost or Iloprost, separately or together with a form of Diethylcarbamazine or Zileuton. Other embodiments may include fluvoxamine. The vasodilator prostacyclin analogue is inhaled. Diethylcarbamazine/Zileuton is inhaled into the lung or administered orally or intravenously. Other embodiments include fluvoxamine. This treatment reduces the progression of the disease, reduces life-threatening exacerbations, and improves the quality of life. The treatment is also for COPD patients with eosinophilia who are incompletely treated with steroids and addresses steroid-unresponsive disease components of COPD including pulmonary hypertension and intravascular inflammation and bronchiectasis. The treatment may include a PDE4 inhibitor and current treatments with existing steroids and beta-adrenergic receptor agonists and/or muscarinic receptor blockers. The treatment is also for ARDS and COVID-19.

Claims24

Dependent claims

A method of treating COPD and inhibiting further lung damage development in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising:

an effective amount of diethylcarbamazine-citrate DEC-citrate);
an effective amount of a prostacyclin analogue selected from the group consisting of Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost;
and a buffering agent, wherein the composition is an aerosol, comprises a propellant, or is in an inhalation delivery device, and wherein the pharmaceutical composition inhibits inflammatory cell infiltration when administered to the lungs.

Dependencies are inferred from the claim text.

Facts

Application

17/539,470Filed 1 Dec 2021 · us provisional application

Priority

1 Dec 2020

Published

US 2022/0168297 A12 Jun 2022

Granted

14 Oct 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…
A61K 9/007
Galenical forms characterised by the site of application: pulmonary tract; Aromatherapy
A61K 9/008
Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy: comprising drug dissolved or…
A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension

Life of this patent

Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension

Life of this patent

Abstract

Claims24